IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

If You Purchased or Paid for REMICADE, A Class Action Settlement Could Affect You.

INFORMATION REGARDING CLASS ACTION SETTLEMENT

A $25,000,000 Settlement has been granted final approval in a class action lawsuit on behalf of consumers and third-party payors regarding the prescription drug Remicade. The class action lawsuit (In re Remicade Antitrust Litigation, No. 2:17-cv-04326-KSM) claims that Defendants Johnson & Johnson and Janssen Biotech, Inc. violated federal and state antitrust and consumer-protection laws by taking action to block competition by new entrants in the infliximab market. Defendants deny any wrongdoing. The Court has not decided who is right.

The Court held the Final Approval hearing on Monday, February 27, 2023. The Court issued the Final Order and Memorandum on Motion for Final Approval on March 15, 2023 approving the Settlement, the plan for allocating the Settlement Fund to Settlement Class Members, and any requests by the attorneys for reimbursement of expenses out of the Settlement Fund or payment of Service Awards to the Named Plaintiffs.

Who Is Included?

The Settlement Class is defined as follows: All persons and entities in the United States and its territories who indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of Defendants’ infliximab (Remicade) from April 5, 2016 through February 28, 2022 (the “Class Period”).

• The following groups are excluded from the Class: (a) Defendants, their officers, directors, management, employees, subsidiaries and affiliates; (b) all federal and state governmental entities except for cities, towns or municipalities with self-funded prescription drug plans; (c) all persons or entities who purchased Defendants’ infliximab (Remicade) for purposes of resale or who purchased infliximab directly from Defendants; (d) fully insured health plans (i.e., health plans that purchased insurance covering 100% of their reimbursement obligation to members); (e) any “flat co-pay” consumers whose purchases of Defendants’ infliximab (Remicade) were paid in part by a third-party payor and whose co-payment was the same regardless of the retail purchase price; (f) pharmacy benefit managers; (g) any judges or justices involved in this action and any members of their immediate families; and (h) any providers (including but not limited to hospitals, clinics, and physicians) who purchase Remicade and are later reimbursed for the provision of Remicade.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT

PARTICIPATE IN THE SETTLEMENT BY SUBMITTING A CLAIM FORM.	The deadline to submit a claim has passed.
EXCLUDE YOURSELF FROM THE SETTLEMENT CLASS	You may choose to exclude yourself, or “optout,” from the Settlement Class if you believe you are a member of the Settlement Class. If you decide to exclude yourself, you will not be bound by any decision in this lawsuit relating to Defendants. This is the only option that allows you to ever be part of any lawsuit (other than this lawsuit) against Defendants relating to the legal claims against Defendants in this case. The deadline for opting out was November 30, 2022.
STAY IN THE LAWSUIT BUT OBJECT TO THE SETTLEMENT	If you object to all or any part of the proposed Settlement, you may write to the Court about why you do not like the proposed Settlement. You may object to the proposed Settlement only if you have not excluded yourself from the Settlement Class. The deadline for objecting was November 30, 2022.
GET MORE INFORMATION	If you would like to get more information about the case or the Settlement, you can send questions to the lawyers or the Settlement Administrator identified in the Notice.

For the purpose of searching purchase records, the Remicade product codes are as follows:

Product	NDC-9	NDC-11	HCPCS/J Code
Remicade	57894-0030	57894-0030-01	J1745